Pliant Therapeutics to Cut About 45% of Jobs to Save Cash

Pliant Therapeutics said its cutting about 45% of its workforce as the biotech company looks to extend its cash runway for late-stage clinical trials.

• Restructuring aims to cut costs as the company awaits topline data from Phase 2b/3 BEACON-IPF trial of bexotegrast in patients with idiopathic pulmonary fibrosis
  • Expects trial data in the 2Q
• Sees about $3.6 million charge from severance and related benefits
• Sees cuts to be completed by end of 2Q and

To view the source of this information, click here and here

To contact the reporter on this story:
Cameron Baker in Boston at cbaker225@bloomberg.net

To ...